Revised: 29 September 2015
Medsafe is the New Zealand Medicines and Medical Devices Safety Authority. It is a business unit of the Ministry of Health and is the authority responsible for the regulation of therapeutic products in New Zealand.
Medsafe's mission is
To enhance the health of New Zealanders
by regulating medicines and medical devices
to maximise safety and benefit.
Medsafe has around 60 staff operating out of two offices, with centralised administrative functions, product approval and standard setting based at the head office in Wellington. Investigation and Border Control functions are based in Auckland. Medsafe's management structure is shown in the following organisation chart.
In carrying out its functions, Medsafe is accountable to the Ministry of Health, and through the Ministry to the Minister of Health. It is also accountable to the pharmaceutical industry for those activities which are funded by fees collected from the industry.
Medsafe is responsible for administering the Medicines Act 1981
and Regulations 1984.
Enquires relating to pharmacy licensing and the Misuse of Drugs Regulations 1977 should be referred to Medicines Control officers.
Medsafe regulates products used for a therapeutic purpose. These include:
"Therapeutic purpose" is defined in Section 4 of the Medicines Act, and includes the treatment, diagnosis and prevention of disease or the modification of a physiological function. It also includes cleaning, soaking or lubricating contact lenses, effecting contraception or inducing anaesthesia.
"Medicine" is defined in Section 3 of the Medicines Act. A product is a medicine if it has a pharmacological effect and is used in humans primarily for a therapeutic purpose.
"Medical device" is defined in Section 3A of the Medicines Act. Medical devices exert their therapeutic effect by physical rather than pharmacological means. The term covers products ranging from wound dressings to heart valves.
For further information about the products regulated by Medsafe and the types of controls used, you should:
The Medicines legislation manages the risk of avoidable harm associated with the use of medicines by ensuring that:
Medsafe is responsible for applying a framework of controls designed to ensure that the therapeutic products available in New Zealand are those that can be expected to have greater benefits than risks if used appropriately. This is achieved through:
Pre-marketing approval must be obtained for new and changed medicines. New medicines cannot be marketed in New Zealand without the consent of the Minister of Health. Medicines to which changes have been made cannot be marketed without the consent of the Director-General of Health. Data that satisfactorily establish the quality, safety and efficacy of the product, for the purposes for which it is to be used, must be submitted for evaluation before consent can be granted.
Medsafe is not involved in funding medicines; this is the responsibility of PHARMAC.
Post-marketing surveillance monitors the safety of medicines and medical devices in use. Products shown to be unsafe are removed from use, and prescribers are advised about new safety information for products. Post-marketing surveillance is achieved through activities such as:
In working to achieve our mission, we will:
Medsafe administers the following legislation.
For free public access to New Zealand legislation: www.legislation.govt.nz